Vice President and Head of In Vitro Diagnostics,
Roche Diagnostics K.K.
Facilitator: Tsutomu Nobori, Professor, Depｔ. of Molecular and Laboratory, Mie University Graduate School of Medicine
After the 3 speeches, the speakers will join a Panel Discussion moderated by Tsutomu Nobori.
Exploring Personalized Healthcare (PHC) Innovative Approaches in Neuroscience Drug Discovery
Emilio Merlo Pich
Head, Clinical Imaging, Neuroscience DTA pRED,
F. Hoffmann-La Roche Ltd.
Roche has already established Personalized Health Care (PHC) expertise with breast, gastric, skin and lung cancer, as well as HIV and Hepatitis C. The company is currently engaged in exploring novel PHC approaches in Neurologic and Psychiatric disorders with high unmet needs such as Alzheimer's Disease (AD), Schizophrenia (SCZ) and Autism Spectrum Disorders. For example, molecular biomarkers and neuroimaging were implemented to identify specific sub-population of AD patients that are expected to respond better to a novel treatment. The use of other technologies aimed to deliver a more effective drug discovery and disease treatment will be also discussed in this lecture.
Emilio Merlo Pich, MD, graduated in Medicine and Neurology at the University of Bologna, Italy, started an academic career at the University of Modena and worked at Karolinska Institute (Stockholm) and the Scripps Research Institute (La Jolla, CA). He is currently the Head of the Clinical Imaging in the Neuroscience DTA of F. Hoffman- La Roche, Basel Switzerland. He previously worked in GlaxoSmithKline (GSK) covering several roles of responsibility, including Director of Experimental Medicine in the Psychiatry CEDD and Head of Discovery Performance Units in neuroscience research in the GSK premises of Verona and Philadelphia.
Development and Perspective of Molecular Diagnosis for Multiple Alterations
Chief, Dept. of Pathology & Molecular Diagnostics,
Aichi Cancer Center Hospital
Recent development of molecular oncology and related targeted therapy for cancer is requiring analysis of multiple genetic alterations that has not been touched in the companion diagnostics. This lecture focuses on practical issues and perspective in applying multi-marker analysis in clinical practice.
Medical Care Innovation in Japan
―Accelerating Regulatory Science Initiative for Personalized Medicine―
Evaluation and Licensing Div., Pharmaceutical and Food Safety Bureau,
Ministry of Health, Labour and Welfare
Amid great changes in the priorities of public health across the world, Japan needs to foster medical innovation with a view to making contributions to the world utilizing Japan's uniqueness in the field. To this end, the government, academia and private sector must strengthen their mutual cooperation based on the understanding of their respective roles. The presentation will introduce current research of regulatory science focusing on methods to evaluate companion diagnostics in linkage with the evaluation of pharmaceuticals, and also our measures for personalized medicine in the context of the Japanese regulatory system.